Global Diuretics Market

Diuretics Comprehensive Study by Type (Thiazide diuretics, Loop diuretics, Potassium-sparing diuretics), Application (Hypertension, Edema, Hypercalciuria, Diabetes, Insipidus, Others), Distribution Channel (Hospital pharmacies, Clinics, Hospitals, Retail pharmacies, Online pharmacies), Indication Type (Hypertension, Glaucoma, Heart Failure, Kidney Stones), Dosage (Oral, Intravenous) Players and Region - Global Market Outlook to 2030

Diuretics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Diuretics
A Diuretic is a class of drugs which is also known as water pills, It is a kind of medicine that cures diseases like cardiovascular diseases, nephrological and urological disorders. This type of drug helps in increasing the amount of water and salt which is expelled from the body as urine. These drugs are commonly used to treat high blood pressure, which is considered as the most common symptom for many diseases. According to the World Health Organization, the number of deaths caused by these diseases is expected to surpass 23 million by 2030. Hence it is necessary to consume diuretics drugs, this drug help in reducing the level of fluid in blood vessels, which in turn helps n reducing blood pressure. An increasingly aging population coupled with the prevalence of chronic diseases are driving the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global diuretics market is fragmented, with a prominent market player acquiring a sizable portion. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. The key market players are also constantly focus on R&D to supply industries with the most efficient and cost effective. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Diuretics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline (United Kingdom), Meda Pharmaceuticals (United Arab Emirates), Roche (Switzerland), Aton Pharma (United States), Sanofi-aventis (United States), Centaur Pharmaceuticals Pvt Ltd (India), Validus Pharmaceuticals LLC (United States), Meda Manufacturing GmbH (Germany), Valeant Pharmaceuticals International, Inc. (Canada) and Actavis Generics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer Inc.(United States), Merck & Co., Inc (United States)., Paddock Laboratories LLC. (United States) and Perrigo Pharmaceuticals Company (Ireland).

Segmentation Overview
AMA Research has segmented the market of Global Diuretics market by Type (Thiazide diuretics, Loop diuretics and Potassium-sparing diuretics), Application (Hypertension, Edema, Hypercalciuria, Diabetes, Insipidus and Others) and Region.



On the basis of geography, the market of Diuretics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel , the sub-segment i.e. Hospital pharmacies will boost the Diuretics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication Type, the sub-segment i.e. Hypertension will boost the Diuretics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage, the sub-segment i.e. Oral will boost the Diuretics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising prevalence of Hypertensive Complications and Increasing Government Initiatives Towards the Patent Exclusivity for new Drug Applications

Market Growth Drivers:
Rising Population with Numerous Cardiac Diseases Globally and Increasing Large Population, Increasing Disposable Income, and Growing Awareness among Patients

Challenges:
Concern Related to the Side Effects of these Drugs Such as Headache, Dizziness and Kidney Failure and Lack of Knowledge About this Drugs

Restraints:
Competition from Biosimilars, Complex Drug Development Process and Multiple Major Drug Patent Expiration

Opportunities:
Growing Geriatric Population in Europe and the Middle East & Africa are Propelling a Significant Growth Opportunities

Market Leaders and their expansionary development strategies
In October 2023, Sun Pharma, a leading Indian pharmaceutical company, announced a partnership with Arrow Therapeutics to develop and commercialize a novel potassium-sparing diuretic for the treatment of hypertension and heart failure. This collaboration leverages Sun Pharma's expertise in drug development and commercialization with Arrow's innovative diuretic technology.
In December 2023, Viatris, a global pharmaceutical company, launched a new generic version of furosemide, a loop diuretic commonly used to treat edema and high blood pressure. This launch provides patients with a more affordable option for this essential medication.


Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organizations, Government Agencies and Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Thiazide diuretics
  • Loop diuretics
  • Potassium-sparing diuretics
By Application
  • Hypertension
  • Edema
  • Hypercalciuria
  • Diabetes
  • Insipidus
  • Others
By Distribution Channel
  • Hospital pharmacies
  • Clinics
  • Hospitals
  • Retail pharmacies
  • Online pharmacies

By Indication Type
  • Hypertension
  • Glaucoma
  • Heart Failure
  • Kidney Stones

By Dosage
  • Oral
  • Intravenous

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Population with Numerous Cardiac Diseases Globally
      • 3.2.2. Increasing Large Population, Increasing Disposable Income, and Growing Awareness among Patients
    • 3.3. Market Challenges
      • 3.3.1. Concern Related to the Side Effects of these Drugs Such as Headache, Dizziness and Kidney Failure
      • 3.3.2. Lack of Knowledge About this Drugs
    • 3.4. Market Trends
      • 3.4.1. Rising prevalence of Hypertensive Complications and Increasing Government Initiatives Towards the Patent Exclusivity for new Drug Applications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Diuretics, by Type, Application, Distribution Channel , Indication Type, Dosage and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Diuretics (Volume)
      • 5.2.1. Global Diuretics by: Type (Volume)
        • 5.2.1.1. Thiazide diuretics
        • 5.2.1.2. Loop diuretics
        • 5.2.1.3. Potassium-sparing diuretics
      • 5.2.2. Global Diuretics by: Application (Volume)
        • 5.2.2.1. Hypertension
        • 5.2.2.2. Edema
        • 5.2.2.3. Hypercalciuria
        • 5.2.2.4. Diabetes
        • 5.2.2.5. Insipidus
        • 5.2.2.6. Others
      • 5.2.3. Global Diuretics by: Dosage (Volume)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
      • 5.2.4. Global Diuretics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Diuretics (Price)
      • 5.3.1. Global Diuretics by: Type (Price)
  • 6. Diuretics: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. GlaxoSmithKline (United Kingdom)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Meda Pharmaceuticals (United Arab Emirates)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. Roche (Switzerland)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Aton Pharma (United States)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Sanofi-aventis (United States)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Centaur Pharmaceuticals Pvt Ltd (India)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Validus Pharmaceuticals LLC (United States)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Meda Manufacturing GmbH (Germany)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Valeant Pharmaceuticals International, Inc. (Canada)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Actavis Generics (United States)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Diuretics Sale, by Type, Application, Distribution Channel , Indication Type, Dosage and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Diuretics (Volume)
      • 7.2.1. Global Diuretics by: Type (Volume)
        • 7.2.1.1. Thiazide diuretics
        • 7.2.1.2. Loop diuretics
        • 7.2.1.3. Potassium-sparing diuretics
      • 7.2.2. Global Diuretics by: Application (Volume)
        • 7.2.2.1. Hypertension
        • 7.2.2.2. Edema
        • 7.2.2.3. Hypercalciuria
        • 7.2.2.4. Diabetes
        • 7.2.2.5. Insipidus
        • 7.2.2.6. Others
      • 7.2.3. Global Diuretics by: Dosage (Volume)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
      • 7.2.4. Global Diuretics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Diuretics (Price)
      • 7.3.1. Global Diuretics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diuretics Sales: by Type(Units)
  • Table 2. Diuretics Sales Thiazide diuretics , by Region Units (2018-2023)
  • Table 3. Diuretics Sales Loop diuretics , by Region Units (2018-2023)
  • Table 4. Diuretics Sales Potassium-sparing diuretics , by Region Units (2018-2023)
  • Table 5. Diuretics Sales: by Application(Units)
  • Table 6. Diuretics Sales Hypertension , by Region Units (2018-2023)
  • Table 7. Diuretics Sales Edema , by Region Units (2018-2023)
  • Table 8. Diuretics Sales Hypercalciuria , by Region Units (2018-2023)
  • Table 9. Diuretics Sales Diabetes , by Region Units (2018-2023)
  • Table 10. Diuretics Sales Insipidus , by Region Units (2018-2023)
  • Table 11. Diuretics Sales Others , by Region Units (2018-2023)
  • Table 12. Diuretics Sales: by Dosage(Units)
  • Table 13. Diuretics Sales Oral , by Region Units (2018-2023)
  • Table 14. Diuretics Sales Intravenous , by Region Units (2018-2023)
  • Table 15. South America Diuretics Sales, by Country Units (2018-2023)
  • Table 16. South America Diuretics Sales, by Type Units (2018-2023)
  • Table 17. South America Diuretics Sales, by Application Units (2018-2023)
  • Table 18. South America Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 19. South America Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 20. South America Diuretics Sales, by Dosage Units (2018-2023)
  • Table 21. Brazil Diuretics Sales, by Type Units (2018-2023)
  • Table 22. Brazil Diuretics Sales, by Application Units (2018-2023)
  • Table 23. Brazil Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 24. Brazil Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 25. Brazil Diuretics Sales, by Dosage Units (2018-2023)
  • Table 26. Argentina Diuretics Sales, by Type Units (2018-2023)
  • Table 27. Argentina Diuretics Sales, by Application Units (2018-2023)
  • Table 28. Argentina Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 29. Argentina Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 30. Argentina Diuretics Sales, by Dosage Units (2018-2023)
  • Table 31. Rest of South America Diuretics Sales, by Type Units (2018-2023)
  • Table 32. Rest of South America Diuretics Sales, by Application Units (2018-2023)
  • Table 33. Rest of South America Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 34. Rest of South America Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 35. Rest of South America Diuretics Sales, by Dosage Units (2018-2023)
  • Table 36. Asia Pacific Diuretics Sales, by Country Units (2018-2023)
  • Table 37. Asia Pacific Diuretics Sales, by Type Units (2018-2023)
  • Table 38. Asia Pacific Diuretics Sales, by Application Units (2018-2023)
  • Table 39. Asia Pacific Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 40. Asia Pacific Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 41. Asia Pacific Diuretics Sales, by Dosage Units (2018-2023)
  • Table 42. China Diuretics Sales, by Type Units (2018-2023)
  • Table 43. China Diuretics Sales, by Application Units (2018-2023)
  • Table 44. China Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 45. China Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 46. China Diuretics Sales, by Dosage Units (2018-2023)
  • Table 47. Japan Diuretics Sales, by Type Units (2018-2023)
  • Table 48. Japan Diuretics Sales, by Application Units (2018-2023)
  • Table 49. Japan Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 50. Japan Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 51. Japan Diuretics Sales, by Dosage Units (2018-2023)
  • Table 52. India Diuretics Sales, by Type Units (2018-2023)
  • Table 53. India Diuretics Sales, by Application Units (2018-2023)
  • Table 54. India Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 55. India Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 56. India Diuretics Sales, by Dosage Units (2018-2023)
  • Table 57. South Korea Diuretics Sales, by Type Units (2018-2023)
  • Table 58. South Korea Diuretics Sales, by Application Units (2018-2023)
  • Table 59. South Korea Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 60. South Korea Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 61. South Korea Diuretics Sales, by Dosage Units (2018-2023)
  • Table 62. Taiwan Diuretics Sales, by Type Units (2018-2023)
  • Table 63. Taiwan Diuretics Sales, by Application Units (2018-2023)
  • Table 64. Taiwan Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 65. Taiwan Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 66. Taiwan Diuretics Sales, by Dosage Units (2018-2023)
  • Table 67. Australia Diuretics Sales, by Type Units (2018-2023)
  • Table 68. Australia Diuretics Sales, by Application Units (2018-2023)
  • Table 69. Australia Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 70. Australia Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 71. Australia Diuretics Sales, by Dosage Units (2018-2023)
  • Table 72. Rest of Asia-Pacific Diuretics Sales, by Type Units (2018-2023)
  • Table 73. Rest of Asia-Pacific Diuretics Sales, by Application Units (2018-2023)
  • Table 74. Rest of Asia-Pacific Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 75. Rest of Asia-Pacific Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 76. Rest of Asia-Pacific Diuretics Sales, by Dosage Units (2018-2023)
  • Table 77. Europe Diuretics Sales, by Country Units (2018-2023)
  • Table 78. Europe Diuretics Sales, by Type Units (2018-2023)
  • Table 79. Europe Diuretics Sales, by Application Units (2018-2023)
  • Table 80. Europe Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 81. Europe Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 82. Europe Diuretics Sales, by Dosage Units (2018-2023)
  • Table 83. Germany Diuretics Sales, by Type Units (2018-2023)
  • Table 84. Germany Diuretics Sales, by Application Units (2018-2023)
  • Table 85. Germany Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 86. Germany Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 87. Germany Diuretics Sales, by Dosage Units (2018-2023)
  • Table 88. France Diuretics Sales, by Type Units (2018-2023)
  • Table 89. France Diuretics Sales, by Application Units (2018-2023)
  • Table 90. France Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 91. France Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 92. France Diuretics Sales, by Dosage Units (2018-2023)
  • Table 93. Italy Diuretics Sales, by Type Units (2018-2023)
  • Table 94. Italy Diuretics Sales, by Application Units (2018-2023)
  • Table 95. Italy Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 96. Italy Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 97. Italy Diuretics Sales, by Dosage Units (2018-2023)
  • Table 98. United Kingdom Diuretics Sales, by Type Units (2018-2023)
  • Table 99. United Kingdom Diuretics Sales, by Application Units (2018-2023)
  • Table 100. United Kingdom Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 101. United Kingdom Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 102. United Kingdom Diuretics Sales, by Dosage Units (2018-2023)
  • Table 103. Netherlands Diuretics Sales, by Type Units (2018-2023)
  • Table 104. Netherlands Diuretics Sales, by Application Units (2018-2023)
  • Table 105. Netherlands Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 106. Netherlands Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 107. Netherlands Diuretics Sales, by Dosage Units (2018-2023)
  • Table 108. Rest of Europe Diuretics Sales, by Type Units (2018-2023)
  • Table 109. Rest of Europe Diuretics Sales, by Application Units (2018-2023)
  • Table 110. Rest of Europe Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 111. Rest of Europe Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 112. Rest of Europe Diuretics Sales, by Dosage Units (2018-2023)
  • Table 113. MEA Diuretics Sales, by Country Units (2018-2023)
  • Table 114. MEA Diuretics Sales, by Type Units (2018-2023)
  • Table 115. MEA Diuretics Sales, by Application Units (2018-2023)
  • Table 116. MEA Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 117. MEA Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 118. MEA Diuretics Sales, by Dosage Units (2018-2023)
  • Table 119. Middle East Diuretics Sales, by Type Units (2018-2023)
  • Table 120. Middle East Diuretics Sales, by Application Units (2018-2023)
  • Table 121. Middle East Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 122. Middle East Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 123. Middle East Diuretics Sales, by Dosage Units (2018-2023)
  • Table 124. Africa Diuretics Sales, by Type Units (2018-2023)
  • Table 125. Africa Diuretics Sales, by Application Units (2018-2023)
  • Table 126. Africa Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 127. Africa Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 128. Africa Diuretics Sales, by Dosage Units (2018-2023)
  • Table 129. North America Diuretics Sales, by Country Units (2018-2023)
  • Table 130. North America Diuretics Sales, by Type Units (2018-2023)
  • Table 131. North America Diuretics Sales, by Application Units (2018-2023)
  • Table 132. North America Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 133. North America Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 134. North America Diuretics Sales, by Dosage Units (2018-2023)
  • Table 135. United States Diuretics Sales, by Type Units (2018-2023)
  • Table 136. United States Diuretics Sales, by Application Units (2018-2023)
  • Table 137. United States Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 138. United States Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 139. United States Diuretics Sales, by Dosage Units (2018-2023)
  • Table 140. Canada Diuretics Sales, by Type Units (2018-2023)
  • Table 141. Canada Diuretics Sales, by Application Units (2018-2023)
  • Table 142. Canada Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 143. Canada Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 144. Canada Diuretics Sales, by Dosage Units (2018-2023)
  • Table 145. Mexico Diuretics Sales, by Type Units (2018-2023)
  • Table 146. Mexico Diuretics Sales, by Application Units (2018-2023)
  • Table 147. Mexico Diuretics Sales, by Distribution Channel Units (2018-2023)
  • Table 148. Mexico Diuretics Sales, by Indication Type Units (2018-2023)
  • Table 149. Mexico Diuretics Sales, by Dosage Units (2018-2023)
  • Table 150. Diuretics: by Type(USD/Units)
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Diuretics Sales: by Type(Units)
  • Table 162. Diuretics Sales Thiazide diuretics , by Region Units (2025-2030)
  • Table 163. Diuretics Sales Loop diuretics , by Region Units (2025-2030)
  • Table 164. Diuretics Sales Potassium-sparing diuretics , by Region Units (2025-2030)
  • Table 165. Diuretics Sales: by Application(Units)
  • Table 166. Diuretics Sales Hypertension , by Region Units (2025-2030)
  • Table 167. Diuretics Sales Edema , by Region Units (2025-2030)
  • Table 168. Diuretics Sales Hypercalciuria , by Region Units (2025-2030)
  • Table 169. Diuretics Sales Diabetes , by Region Units (2025-2030)
  • Table 170. Diuretics Sales Insipidus , by Region Units (2025-2030)
  • Table 171. Diuretics Sales Others , by Region Units (2025-2030)
  • Table 172. Diuretics Sales: by Dosage(Units)
  • Table 173. Diuretics Sales Oral , by Region Units (2025-2030)
  • Table 174. Diuretics Sales Intravenous , by Region Units (2025-2030)
  • Table 175. South America Diuretics Sales, by Country Units (2025-2030)
  • Table 176. South America Diuretics Sales, by Type Units (2025-2030)
  • Table 177. South America Diuretics Sales, by Application Units (2025-2030)
  • Table 178. South America Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 179. South America Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 180. South America Diuretics Sales, by Dosage Units (2025-2030)
  • Table 181. Brazil Diuretics Sales, by Type Units (2025-2030)
  • Table 182. Brazil Diuretics Sales, by Application Units (2025-2030)
  • Table 183. Brazil Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 184. Brazil Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 185. Brazil Diuretics Sales, by Dosage Units (2025-2030)
  • Table 186. Argentina Diuretics Sales, by Type Units (2025-2030)
  • Table 187. Argentina Diuretics Sales, by Application Units (2025-2030)
  • Table 188. Argentina Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 189. Argentina Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 190. Argentina Diuretics Sales, by Dosage Units (2025-2030)
  • Table 191. Rest of South America Diuretics Sales, by Type Units (2025-2030)
  • Table 192. Rest of South America Diuretics Sales, by Application Units (2025-2030)
  • Table 193. Rest of South America Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 194. Rest of South America Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 195. Rest of South America Diuretics Sales, by Dosage Units (2025-2030)
  • Table 196. Asia Pacific Diuretics Sales, by Country Units (2025-2030)
  • Table 197. Asia Pacific Diuretics Sales, by Type Units (2025-2030)
  • Table 198. Asia Pacific Diuretics Sales, by Application Units (2025-2030)
  • Table 199. Asia Pacific Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 200. Asia Pacific Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 201. Asia Pacific Diuretics Sales, by Dosage Units (2025-2030)
  • Table 202. China Diuretics Sales, by Type Units (2025-2030)
  • Table 203. China Diuretics Sales, by Application Units (2025-2030)
  • Table 204. China Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 205. China Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 206. China Diuretics Sales, by Dosage Units (2025-2030)
  • Table 207. Japan Diuretics Sales, by Type Units (2025-2030)
  • Table 208. Japan Diuretics Sales, by Application Units (2025-2030)
  • Table 209. Japan Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 210. Japan Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 211. Japan Diuretics Sales, by Dosage Units (2025-2030)
  • Table 212. India Diuretics Sales, by Type Units (2025-2030)
  • Table 213. India Diuretics Sales, by Application Units (2025-2030)
  • Table 214. India Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 215. India Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 216. India Diuretics Sales, by Dosage Units (2025-2030)
  • Table 217. South Korea Diuretics Sales, by Type Units (2025-2030)
  • Table 218. South Korea Diuretics Sales, by Application Units (2025-2030)
  • Table 219. South Korea Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 220. South Korea Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 221. South Korea Diuretics Sales, by Dosage Units (2025-2030)
  • Table 222. Taiwan Diuretics Sales, by Type Units (2025-2030)
  • Table 223. Taiwan Diuretics Sales, by Application Units (2025-2030)
  • Table 224. Taiwan Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 225. Taiwan Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 226. Taiwan Diuretics Sales, by Dosage Units (2025-2030)
  • Table 227. Australia Diuretics Sales, by Type Units (2025-2030)
  • Table 228. Australia Diuretics Sales, by Application Units (2025-2030)
  • Table 229. Australia Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 230. Australia Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 231. Australia Diuretics Sales, by Dosage Units (2025-2030)
  • Table 232. Rest of Asia-Pacific Diuretics Sales, by Type Units (2025-2030)
  • Table 233. Rest of Asia-Pacific Diuretics Sales, by Application Units (2025-2030)
  • Table 234. Rest of Asia-Pacific Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 235. Rest of Asia-Pacific Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 236. Rest of Asia-Pacific Diuretics Sales, by Dosage Units (2025-2030)
  • Table 237. Europe Diuretics Sales, by Country Units (2025-2030)
  • Table 238. Europe Diuretics Sales, by Type Units (2025-2030)
  • Table 239. Europe Diuretics Sales, by Application Units (2025-2030)
  • Table 240. Europe Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 241. Europe Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 242. Europe Diuretics Sales, by Dosage Units (2025-2030)
  • Table 243. Germany Diuretics Sales, by Type Units (2025-2030)
  • Table 244. Germany Diuretics Sales, by Application Units (2025-2030)
  • Table 245. Germany Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 246. Germany Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 247. Germany Diuretics Sales, by Dosage Units (2025-2030)
  • Table 248. France Diuretics Sales, by Type Units (2025-2030)
  • Table 249. France Diuretics Sales, by Application Units (2025-2030)
  • Table 250. France Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 251. France Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 252. France Diuretics Sales, by Dosage Units (2025-2030)
  • Table 253. Italy Diuretics Sales, by Type Units (2025-2030)
  • Table 254. Italy Diuretics Sales, by Application Units (2025-2030)
  • Table 255. Italy Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 256. Italy Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 257. Italy Diuretics Sales, by Dosage Units (2025-2030)
  • Table 258. United Kingdom Diuretics Sales, by Type Units (2025-2030)
  • Table 259. United Kingdom Diuretics Sales, by Application Units (2025-2030)
  • Table 260. United Kingdom Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 261. United Kingdom Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 262. United Kingdom Diuretics Sales, by Dosage Units (2025-2030)
  • Table 263. Netherlands Diuretics Sales, by Type Units (2025-2030)
  • Table 264. Netherlands Diuretics Sales, by Application Units (2025-2030)
  • Table 265. Netherlands Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 266. Netherlands Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 267. Netherlands Diuretics Sales, by Dosage Units (2025-2030)
  • Table 268. Rest of Europe Diuretics Sales, by Type Units (2025-2030)
  • Table 269. Rest of Europe Diuretics Sales, by Application Units (2025-2030)
  • Table 270. Rest of Europe Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 271. Rest of Europe Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 272. Rest of Europe Diuretics Sales, by Dosage Units (2025-2030)
  • Table 273. MEA Diuretics Sales, by Country Units (2025-2030)
  • Table 274. MEA Diuretics Sales, by Type Units (2025-2030)
  • Table 275. MEA Diuretics Sales, by Application Units (2025-2030)
  • Table 276. MEA Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 277. MEA Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 278. MEA Diuretics Sales, by Dosage Units (2025-2030)
  • Table 279. Middle East Diuretics Sales, by Type Units (2025-2030)
  • Table 280. Middle East Diuretics Sales, by Application Units (2025-2030)
  • Table 281. Middle East Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 282. Middle East Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 283. Middle East Diuretics Sales, by Dosage Units (2025-2030)
  • Table 284. Africa Diuretics Sales, by Type Units (2025-2030)
  • Table 285. Africa Diuretics Sales, by Application Units (2025-2030)
  • Table 286. Africa Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 287. Africa Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 288. Africa Diuretics Sales, by Dosage Units (2025-2030)
  • Table 289. North America Diuretics Sales, by Country Units (2025-2030)
  • Table 290. North America Diuretics Sales, by Type Units (2025-2030)
  • Table 291. North America Diuretics Sales, by Application Units (2025-2030)
  • Table 292. North America Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 293. North America Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 294. North America Diuretics Sales, by Dosage Units (2025-2030)
  • Table 295. United States Diuretics Sales, by Type Units (2025-2030)
  • Table 296. United States Diuretics Sales, by Application Units (2025-2030)
  • Table 297. United States Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 298. United States Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 299. United States Diuretics Sales, by Dosage Units (2025-2030)
  • Table 300. Canada Diuretics Sales, by Type Units (2025-2030)
  • Table 301. Canada Diuretics Sales, by Application Units (2025-2030)
  • Table 302. Canada Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 303. Canada Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 304. Canada Diuretics Sales, by Dosage Units (2025-2030)
  • Table 305. Mexico Diuretics Sales, by Type Units (2025-2030)
  • Table 306. Mexico Diuretics Sales, by Application Units (2025-2030)
  • Table 307. Mexico Diuretics Sales, by Distribution Channel Units (2025-2030)
  • Table 308. Mexico Diuretics Sales, by Indication Type Units (2025-2030)
  • Table 309. Mexico Diuretics Sales, by Dosage Units (2025-2030)
  • Table 310. Diuretics: by Type(USD/Units)
  • Table 311. Research Programs/Design for This Report
  • Table 312. Key Data Information from Secondary Sources
  • Table 313. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diuretics: by Type Units (2018-2023)
  • Figure 5. Global Diuretics: by Application Units (2018-2023)
  • Figure 6. Global Diuretics: by Dosage Units (2018-2023)
  • Figure 7. South America Diuretics Share (%), by Country
  • Figure 8. Asia Pacific Diuretics Share (%), by Country
  • Figure 9. Europe Diuretics Share (%), by Country
  • Figure 10. MEA Diuretics Share (%), by Country
  • Figure 11. North America Diuretics Share (%), by Country
  • Figure 12. Global Diuretics: by Type USD/Units (2018-2023)
  • Figure 13. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 14. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 15. Meda Pharmaceuticals (United Arab Emirates) Revenue, Net Income and Gross profit
  • Figure 16. Meda Pharmaceuticals (United Arab Emirates) Revenue: by Geography 2023
  • Figure 17. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 19. Aton Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 20. Aton Pharma (United States) Revenue: by Geography 2023
  • Figure 21. Sanofi-aventis (United States) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi-aventis (United States) Revenue: by Geography 2023
  • Figure 23. Centaur Pharmaceuticals Pvt Ltd (India) Revenue, Net Income and Gross profit
  • Figure 24. Centaur Pharmaceuticals Pvt Ltd (India) Revenue: by Geography 2023
  • Figure 25. Validus Pharmaceuticals LLC (United States) Revenue, Net Income and Gross profit
  • Figure 26. Validus Pharmaceuticals LLC (United States) Revenue: by Geography 2023
  • Figure 27. Meda Manufacturing GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Meda Manufacturing GmbH (Germany) Revenue: by Geography 2023
  • Figure 29. Valeant Pharmaceuticals International, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Valeant Pharmaceuticals International, Inc. (Canada) Revenue: by Geography 2023
  • Figure 31. Actavis Generics (United States) Revenue, Net Income and Gross profit
  • Figure 32. Actavis Generics (United States) Revenue: by Geography 2023
  • Figure 33. Global Diuretics: by Type Units (2025-2030)
  • Figure 34. Global Diuretics: by Application Units (2025-2030)
  • Figure 35. Global Diuretics: by Dosage Units (2025-2030)
  • Figure 36. South America Diuretics Share (%), by Country
  • Figure 37. Asia Pacific Diuretics Share (%), by Country
  • Figure 38. Europe Diuretics Share (%), by Country
  • Figure 39. MEA Diuretics Share (%), by Country
  • Figure 40. North America Diuretics Share (%), by Country
  • Figure 41. Global Diuretics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Meda Pharmaceuticals (United Arab Emirates)
  • Roche (Switzerland)
  • Aton Pharma (United States)
  • Sanofi-aventis (United States)
  • Centaur Pharmaceuticals Pvt Ltd (India)
  • Validus Pharmaceuticals LLC (United States)
  • Meda Manufacturing GmbH (Germany)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Actavis Generics (United States)
Additional players considered in the study are as follows:
Pfizer Inc.(United States) , Merck & Co., Inc (United States). , Paddock Laboratories LLC. (United States) , Perrigo Pharmaceuticals Company (Ireland)
Select User Access Type

Key Highlights of Report


Jan 2024 244 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diuretics Market Quantitative research analysis
Global Diuretics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline (United Kingdom), Meda Pharmaceuticals (United Arab Emirates), Roche (Switzerland), Aton Pharma (United States), Sanofi-aventis (United States), Centaur Pharmaceuticals Pvt Ltd (India), Validus Pharmaceuticals LLC (United States), Meda Manufacturing GmbH (Germany), Valeant Pharmaceuticals International, Inc. (Canada) and Actavis Generics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising prevalence of Hypertensive Complications and Increasing Government Initiatives Towards the Patent Exclusivity for new Drug Applications" is seen as one of major influencing trends for Diuretics Market during projected period 2023-2030.
The Diuretics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Diuretics Market Report?

Have a Query? Click Here

Other Related Reports

Therapeutic Vaccines Comprehensive Study by Category (Antigen Vaccines, Dendritic Cell Vaccines, DNA Vaccines, Tumor Cell Vaccines), Disease (Autoimmune Disease, Cancer, Neurological Diseases, Infect...
$ 3650
Traumatic Brain Injury Therapeutics Comprehensive Study by Type (Immediate emergency care, Medications (Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-...
$ 3800
ENT Disorder Treatment Comprehensive Study by Type (Devices, Therapy, Medications (Nasal Spray, Drops, Tablets), Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Setti...
$ 3650
Scar Treatment Comprehensive Study by Type (Surgical, Laser, Topical, Injectable, Other), Application (Hospitals, Dermatology Clinics, Other), Scar (Atrophic, Hypertrophic and Keloid, Contracture, St...
$ 3500
GERD Comprehensive Study by End Users (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral, Others), Drug Class (Antacids, Proton Pump Inhibitors, H...
$ 3800
CO2 Incubators Comprehensive Study by Type (Water Jacketed CO2 Incubators, Air-Jacketed CO2 Incubators, Direct Heat CO2 Incubators), Application (Industrial, Biotechnology, Agriculture, Others), Capa...
$ 3450